NCT01645761

Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori

Additive Effect of Endonase on Eradication Rate of the 7-day Standard Proton Pump Inhibitor-based Triple Therapy for Helicobacter Pylori

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: Chuncheon Sacred Heart Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

Conditions

• Gastric Ulcer Associated With Helicobacter Pylori

Interventions

Type	Name	Description
DRUG	Endonase	PPI- based triple therapy with endonase

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2012-07-20
• Last updated: 2014-01-22

Locations

1 site across 1 country: South Korea